• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 3. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 4. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 5. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Chlorobenzenes

Research Update on Methyl 5-(3-chlorophenyl)isoxazole-3-carboxylate (CAS: 660417-41-4) in Chemical Biology and Pharmaceutical Applications

Methyl 5-(3-chlorophenyl)isoxazole-3-carboxylate (CAS: 660417-41-4) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. This heterocyclic isoxazole derivative, characterized by its 3-chlorophenyl substitution pattern, has demonstrated promising biological activities in multiple preclinical studies. Recent literature highlights its potential as a scaffold for developing novel therapeutic agents, particularly in the areas of anti-inflammatory and anticancer drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.3c00562) investigated the compound's mechanism of action as a selective COX-2 inhibitor. The research team employed molecular docking simulations and enzymatic assays to demonstrate that methyl 5-(3-chlorophenyl)isoxazole-3-carboxylate exhibits a unique binding mode to the COX-2 active site, with an IC50 value of 0.87 μM. These findings suggest its potential as a lead compound for developing next-generation anti-inflammatory drugs with reduced gastrointestinal side effects compared to traditional NSAIDs.

In oncology research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024, 58, 128543) reported the compound's ability to inhibit tubulin polymerization through a novel mechanism. The study utilized fluorescence-based assays and electron microscopy to show that methyl 5-(3-chlorophenyl)isoxazole-3-carboxylate disrupts microtubule dynamics at concentrations as low as 1.2 μM, while showing minimal cytotoxicity against normal cell lines. This selective activity profile makes it an attractive candidate for further development as an antimitotic agent.

The compound's synthetic accessibility has also been improved through recent methodological advances. A 2024 paper in Organic Process Research & Development (DOI: 10.1021/acs.oprd.4c00031) described a novel continuous-flow synthesis of methyl 5-(3-chlorophenyl)isoxazole-3-carboxylate that achieves 92% yield with significantly reduced reaction time (15 minutes) compared to traditional batch methods. This technological advancement addresses previous scalability challenges and could facilitate its broader application in drug discovery programs.

Pharmacokinetic studies published in Xenobiotica (2023, 53(8), 567-578) have provided new insights into the compound's metabolic stability and tissue distribution. Using LC-MS/MS analysis in rodent models, researchers found that methyl 5-(3-chlorophenyl)isoxazole-3-carboxylate demonstrates favorable oral bioavailability (68%) and a plasma half-life of 4.2 hours, with preferential accumulation in inflammatory tissues. These properties support its potential for oral administration in therapeutic applications.

Current research directions include structure-activity relationship (SAR) studies to optimize the compound's pharmacological profile. Recent work has focused on modifications at the 3-carboxylate position and exploration of alternative phenyl ring substitutions. Preliminary results presented at the 2024 American Chemical Society National Meeting suggest that certain derivatives maintain the parent compound's biological activity while improving metabolic stability and solubility characteristics.

The growing body of research on methyl 5-(3-chlorophenyl)isoxazole-3-carboxylate (660417-41-4) underscores its versatility as a pharmacophore in medicinal chemistry. Its dual activities in inflammation modulation and cell cycle disruption, combined with recent synthetic and pharmacokinetic advancements, position this compound as a valuable tool for both basic research and drug development. Future studies are expected to explore its potential in combination therapies and targeted delivery systems.

• 7063-99-2(Ethyl 5-phenylisoxazole-3-carboxylate)
• 33282-22-3(5-(4-Chlorophenyl)Isoxazole-3-carboxylic Acid)
• 159427-17-5(Ethyl 5-(2,4-dichlorophenyl)isoxazole-3-carboxylate)
• 371157-18-5(5-(3,5-Dimethylphenyl)-3-isoxazolecarboxylic acid ethyl ester)
• 893638-47-6(Ethyl 5-(m-tolyl)isoxazole-3-carboxylate)
• 81282-12-4(5-(4-Chloro-phenyl)-isoxazole-3-carboxylic acid ethylester)
• 88958-15-0(Ethyl 5-(p-tolyl)isoxazole-3-carboxylate)
• 51677-09-9(methyl 5-phenyl-1,2-oxazole-3-carboxylate)
• 657424-77-6(Ethyl 5-(3-chlorophenyl)isoxazole-3-carboxylate)
• 876710-49-5(5-(3,4-Dichlorophenyl)-1,2-oxazole-3-carboxylic Acid)